Associations between (pharmaco-)genetic markers and postoperative pain after inguinal hernia repair - a prospective study protocol.

Publisher: BioMed Central Country of Publication: England NLM ID: 101319628 Publication Model: Electronic Cited Medium: Internet ISSN: 1755-8794 (Electronic) Linking ISSN: 17558794 NLM ISO Abbreviation: BMC Med Genomics Subsets: MEDLINE

Original Publication: London : BioMed Central

Pain, Postoperative*/genetics ; Pain, Postoperative*/etiology ; Pain, Postoperative*/drug therapy ; Hernia, Inguinal*/surgery; Humans ; Prospective Studies ; Catechol O-Methyltransferase/genetics ; Cytochrome P-450 CYP2D6/genetics ; Receptors, Opioid, mu/genetics ; Receptors, Opioid, mu/metabolism ; Herniorrhaphy/adverse effects ; Male ; Adult ; Female

Background: Postoperative pain is a common complication following surgery, with severity and duration varying between patients. Chronic postoperative pain after inguinal hernia surgery has an incidence rate of approximately 10%. Risk factors for acute and chronic pain following hernia surgery include age, sex, psychosocial factors, and demographic background. Additionally, genetic polymorphisms in enzymes involved in pain mechanisms, as well as the metabolism of analgesics might influence pain perception, pain development, and response to pain medications. Key enzymes include the catechol-o-methyltransferase (COMT), the µ-opioid receptor 1 (OPRM1), and the cytochrome P450 2D6 (CYP2D6). CYP2D6 plays a crucial role in metabolizing analgesics such as tramadol, codeine, and oxycodone. It is also suspected to be involved in the synthesis of catecholamines and endogenous morphines suggesting a potential role in pathophysiology of pain. We hypothesize that the CYP2D6 activity influences the development of postoperative pain after hernia surgery.
Methods: This study is a prospective, observational, multicenter association study investigating adult patients scheduled for inguinal hernia surgery using a robotic-assisted (rTAPP) approach. Patients are enrolled during the preoperative surgical consultation. A buccal swab is collected for genetic testing at this time. Pain at the site of the hernia is assessed using the validated EuraHSQoL score preoperatively and at 2, 4, and 6 weeks postoperatively. Additionally, information on co-medication and details of the surgery will be collected. The planned number of participants is 350 patients. The primary objective is to analyze the association between different genotype-predicted CYP2D6 phenotypes and patient-reported pain intensity 6 weeks after surgery. Secondary objectives include the association between further genetic variants, such as the COMT rs4680 and OPRM1 rs1799971 genotype, and pain severity. Additionally, the potential of pharmacogenetic panel testing to optimize analgesic therapy in hernia surgery patients will be explored.
Discussion: The findings of this study are expected to provide valuable insights into identifying patients at higher risk for postoperative pain before surgery. This knowledge could pave the way for tailored interventions during and after surgery for these specific patients.
Trial Registration: Deutsches Register Klinischer Studien https://www.drks.de/DRKS00034796 Registered on August 07, 2024.
Competing Interests: Declarations. Ethics approval and consent to participate: The local ethics committees (Ethikkommission Nordwest- und Zentralschweiz, Basel, Switzerland, and Kantonale Ethikkommission Zürich, Zürich, Switzerland) approved the described study protocol version 2, dated on July 24, 2024, as of October 01, 2024 (reference number 2024–01080). We will obtain consent from all trial participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)

Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain – update on incidence, risk factors and preventive treatment options. BJA Educ. 2022;22(5):190–6. (PMID: 10.1016/j.bjae.2021.11.008354966459039436)
Schug SA, Lavand’homme P, Barke A, Korwisi B, Rief W, Treede RD, et al. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. Pain. 2019;160(1):45. (PMID: 10.1097/j.pain.000000000000141330586070)
Gerbershagen HJ, Pogatzki-Zahn E, Aduckathil S, Peelen LM, Kappen TH, van Wijck AJM, et al. Procedure-specific risk factor analysis for the development of severe postoperative pain. Anesthesiology. 2014;120(5):1237–45. (PMID: 10.1097/ALN.000000000000010824356102)
Aasvang EK, Gmaehle E, Hansen JB, Gmaehle B, Forman JL, Schwarz J, et al. Predictive risk factors for persistent postherniotomy pain. Anesthesiology. 2010Apr;112(4):957–69. (PMID: 10.1097/ALN.0b013e3181d31ff820234307)
van Veenendaal N, Simons MP, Bonjer HJ. Summary for patients: International guidelines for groin hernia management. Hernia. 2018;22(1):167–8. (PMID: 10.1007/s10029-018-1729-929356909)
Haladu N, Alabi A, Brazzelli M, Imamura M, Ahmed I, Ramsay G, et al. Open versus laparoscopic repair of inguinal hernia: an overview of systematic reviews of randomised controlled trials. Surg Endosc. 2022;36(7):4685–700. (PMID: 10.1007/s00464-022-09161-6352864719160137)
Widder A, Reese L, Lock JF, Wiegering A, Germer CT, Kindl GK, et al. Postoperative Analgesics Score as a Predictor of Chronic Postoperative Inguinal Pain After Inguinal Hernia Repair: Lessons Learned From a Retrospective Analysis. World J Surg. 2023;47(10):2436–43. (PMID: 10.1007/s00268-023-07074-63724832210474177)
Haroutiunian S, Nikolajsen L, Finnerup NB, Jensen TS. The neuropathic component in persistent postsurgical pain: a systematic literature review. Pain. 2013;154(1):95–102. (PMID: 10.1016/j.pain.2012.09.01023273105)
Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet Lond Engl. 2006;367(9522):1618–25. (PMID: 10.1016/S0140-6736(06)68700-X)
Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32. (PMID: 10.1146/annurev.neuro.051508.135531194007242768555)
Hansen MB, Andersen KG, Crawford ME. Pain following the repair of an abdominal hernia. Surg Today. 2010;40(1):8–21. (PMID: 10.1007/s00595-009-4001-120037834)
Lötsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther. 2009Nov 1;124(2):168–84. (PMID: 10.1016/j.pharmthera.2009.06.01019615406)
Palada V, Kaunisto MA, Kalso E. Genetics and genomics in postoperative pain and analgesia. Curr Opin Anaesthesiol. 2018;31(5):569–74. (PMID: 10.1097/ACO.000000000000063329994939)
Young EE, Lariviere WR, Belfer I. Genetic Basis of Pain Variability: Recent Advances. J Med Genet. 2012 Jan;49(1): https://doi.org/10.1136/jmedgenet-2011-100386 .
Vetterlein A, Monzel M, Reuter M. Are catechol-O-methyltransferase gene polymorphisms genetic markers for pain sensitivity after all? – A review and meta-analysis. Neurosci Biobehav Rev. 2023;1(148):105112. (PMID: 10.1016/j.neubiorev.2023.105112)
Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34(13):4202–10. (PMID: 10.1021/bi00013a0087703232)
Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75(5):807–21. (PMID: 10.1086/425589154574041182110)
Chidambaran V, Gang Y, Pilipenko V, Ashton M, Ding L. Systematic Review and Meta-Analysis of Genetic Risk of Developing Chronic Postsurgical Pain. J Pain. 2020;21(1–2):2–24. (PMID: 10.1016/j.jpain.2019.05.00831129315)
Belfer I, Dai F, Kehlet H, Finelli P, Qin L, Bittner R, et al. Association of functional variations in COMT and GCH1 genes with postherniotomy pain and related impairment. Pain. 2015;156(2):273–9. (PMID: 10.1097/01.j.pain.0000460307.48701.b025599448)
Zahari Z, Ismail R. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid Analgesics. Drug Metab Pharmacokinet. 2014;29(1):29–43. (PMID: 10.2133/dmpk.DMPK-13-RV-03223759977)
Schwabedissen MZ, HE. The role of pharmacogenomics in individualized medicine. In: Fischer T, Langanke M, Marschall P, Michl S, editors. Individualized medicine–ethical, economical and historical perspectives. Springer: Cham; 2014. p. 93–112.
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888–96. (PMID: 10.1002/cpt.214933387367)
Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2021;30(10):1105–13. (PMID: 10.1038/s41431-021-00920-y342673379553935)
Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain. 1993;53(3):335. (PMID: 10.1016/0304-3959(93)90229-I8351162)
Candiotti KA, Yang Z, Rodriguez Y, Crescimone A, Sanchez GC, Takacs P, et al. The Impact of CYP2D6 Genetic Polymorphisms on Postoperative Morphine Consumption. Pain Med. 2009;10(5):799–805. (PMID: 10.1111/j.1526-4637.2009.00641.x19523031)
Yang Z, Yang Z, Arheart KL, Morris R, Zhang Y, Rodriguez Y, et al. CYP2D6 Poor Metabolizer Genotype and Smoking Predict Severe Postoperative Pain in Female Patients on Arrival to the Recovery Room. Pain Med. 2012;13(4):604–9. (PMID: 10.1111/j.1526-4637.2012.01296.x22497725)
Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191–200. (PMID: 10.1002/cpt.183032189324)
Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417–23. (PMID: 10.1002/cpt.201532770672)
Muysoms F, Campanelli G, Champault GG, DeBeaux AC, Dietz UA, Jeekel J, et al. EuraHS: the development of an international online platform for registration and outcome measurement of ventral abdominal wall hernia repair. Hernia J Hernias Abdom Wall Surg. 2012;16(3):239–50. (PMID: 10.1007/s10029-012-0912-7)
Welch RA, Lazaruk K, Haque KA, Hyland F, Xiao N, Wronka L, et al. Validation of the performance of a comprehensive genotyping assay panel of single nucleotide polymorphisms in drug metabolism enzyme genes. Hum Mutat. 2008;29(5):750–6. (PMID: 10.1002/humu.2070318327779)
PharmGKB. Gene-specific Information Tables for CYP2D6. https://www.pharmgkb.org/page/cyp2d6RefMaterials Accessed 20 Aug 2024.
Hilfiker R. Schmerzintensität messen. Physiopraxis. 2008;6(11):46–7.
Muysoms FE, Vanlander A, Ceulemans R, Kyle-Leinhase I, Michiels M, Jacobs I, et al. A prospective, multicenter, observational study on quality of life after laparoscopic inguinal hernia repair with ProGrip laparoscopic, self-fixating mesh according to the European Registry for Abdominal Wall Hernias Quality of Life Instrument. Surgery. 2016;160(5):1344–57. (PMID: 10.1016/j.surg.2016.04.02627316825)
Miserez M, Alexandre JH, Campanelli G, Corcione F, Cuccurullo D, Pascual MH, et al. The European hernia society groin hernia classication: simple and easy to remember. Hernia. 2007;11(2):113–6. (PMID: 10.1007/s10029-007-0198-317353992)
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37–44. (PMID: 10.1002/cpt.59727997040)
van Veenendaal N, Foss NB, Miserez M, Pawlak M, Zwaans WAR, Aasvang EKA, narrative review on the non-surgical treatment of chronic postoperative inguinal pain: a challenge for both surgeon and anaesthesiologist. Hernia. cited 2022 Nov 11. Available from: 2022Oct 31. https://doi.org/10.1007/s10029-022-02693-9 .
Hamilton WG, Gargiulo JM, Parks NL. Using pharmacogenetics to structure individual pain management protocols in total knee arthroplasty. Bone Joint J. 2020;102-b(6_Supple_A):73–8. (PMID: 10.1302/0301-620X.102B6.BJJ-2019-1539.R132475277)
Thomas CD, Parvataneni HK, Gray CF, Deen JT, Prieto HA, Pulido LF, et al. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genet Med. 2021;23(4):621–8. (PMID: 10.1038/s41436-020-01050-4334203498525217)
Hamilton WG, Gargiulo JM, Reynolds TR, Parks NL. Prospective Randomized Study Using Pharmacogenetics to Customize Postoperative Pain Medication Following Hip and Knee Arthroplasty. J Arthroplasty. 2022;37(6, Supplement):S76–81. (PMID: 10.1016/j.arth.2022.02.03735279338)
Senagore AJ, Champagne BJ, Dosokey E, Brady J, Steele SR, Reynolds HL, et al. Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol. Am J Surg. 2017;213(3):467–72. (PMID: 10.1016/j.amjsurg.2016.11.00827955884)

Keywords: Analgesics; COMT; CYP2D6; Hernia surgery; OPRM1; Pharmacogenetics; Postoperative pain; rTAPP

EC 2.1.1.6 (Catechol O-Methyltransferase)
EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
0 (Receptors, Opioid, mu)
0 (OPRM1 protein, human)
EC 2.1.1.6 (COMT protein, human)

Date Created: 20241219 Date Completed: 20241219 Latest Revision: 20241219

20241219

10.1186/s12920-024-02064-6

39696400